The Impact of Neoadjuvant Chemotherapy on Lymph Node Harvest and Lymph Node Size in Colorectal Carcinoma

Aim: To clarify the impact of metastatic lymph node size on long-term outcomes in patients undergoing curative colectomy for pathological stage III colon cancer. Patients and Methods: This study enrolled patients who underwent curative colectomy for pStage III colon cancer between January 2013 and December 2015. All patients were divided into four groups based on the short-axis diameter of the largest MLN: Group A, <5 mm; Group B, ≥5 mm and <10 mm; Group C, ≥10 mm and <15 mm; Group D, ≥15 mm. Results: A total of 209 patients were analyzed. The 5-year recurrence-free survival rates of Groups A, B, C, and D were 82.3%, 74.6%, 74.5% and 60.7%, respectively. In multivariate analysis, Group D (hazard ratio=3.95; 95% confidence interval, 1.34-11.65; p=0.01) was independently associated with worse RFS. Conclusion: Bulky MLNs might be a poor prognostic factor in node-positive colon cancer.

Download Full-text

Normal mediastinal lymph node size and shape; CT and cadaver study

Journal of the Korean Radiological Society ◽

10.3348/jkrs.1985.21.3.408 ◽

1985 ◽

Vol 21 (3) ◽

pp. 408

Author(s):

C K Im ◽

K S Lee ◽

M C Han ◽

C W Kim

Keyword(s):

Lymph Node ◽

Mediastinal Lymph Node ◽

Cadaver Study ◽

Size And Shape ◽

Lymph Node Size ◽

Node Size

Download Full-text

Nuclear PTEN deficiency and heterozygous PTEN loss have distinct impacts on brain and lymph node size

Biochemical and Biophysical Research Communications ◽

10.1016/j.bbrc.2021.03.081 ◽

2021 ◽

Vol 555 ◽

pp. 81-88

Author(s):

Atsushi Igarashi ◽

Takashi Kato ◽

Hiromi Sesaki ◽

Miho Iijima

Keyword(s):

Lymph Node ◽

Pten Loss ◽

Lymph Node Size ◽

Node Size

Download Full-text

Clinical Impact of Lymphadenectomy after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Review of Available Data

Journal of Clinical Medicine ◽

10.3390/jcm10020334 ◽

2021 ◽

Vol 10 (2) ◽

pp. 334

Author(s):

Stephanie Seidler ◽

Meriem Koual ◽

Guillaume Achen ◽

Enrica Bentivegna ◽

Laure Fournier ◽

...

Keyword(s):

Ovarian Cancer ◽

Lymph Node ◽

Neoadjuvant Chemotherapy ◽

Epithelial Ovarian Cancer ◽

Lymph Node Dissection ◽

Prospective Trial ◽

Node Dissection ◽

Advanced Epithelial Ovarian Cancer ◽

The Impact ◽

Systematic Lymph Node Dissection

Recent robust data allow for omitting lymph node dissection for patients with advanced epithelial ovarian cancer (EOC) and without any suspicion of lymph node metastases, without compromising recurrence-free survival (RFS), nor overall survival (OS), in the setting of primary surgical treatment. Evidence supporting the same postulate for patients undergoing complete cytoreductive surgery after neoadjuvant chemotherapy (NACT) is lacking. Throughout a systematic literature review, the aim of our study was to evaluate the impact of lymph node dissection in patients undergoing surgery for advanced-stage EOC after NACT. A total of 1094 patients, included in six retrospective series, underwent either systematic, selective or no lymph node dissection. Only one study reveals a positive effect of lymphadenectomy on OS, and two on RFS. The four remaining series fail to demonstrate any beneficial effect on survival, neither for RFS nor OS. All of them highlight the higher peri- and post-operative complication rate associated with systematic lymph node dissection. Despite heterogeneity in the design of the studies included, there seems to be a trend showing no improvement on OS for systematic lymph node dissection in node negative patients. A well-conducted prospective trial is mandatory to evaluate this matter.

Download Full-text